Table 4: Relationship between aberrant P-cadherin immunoexpression and mammary lesions.

Mammary lesions Aberrant P-cadherin immunoreactivity
0123

Hyperplasias1212 (100.00%)0 (0.00%)0 (0.00%)0 (0.00%)
Benign tumours 66 (100.00%)0 (0.00%)0 (0.00%)0 (0.00%)
Malignant tumours3914 (35.90%)10 (25.64%)8 (20.51%)7 (17.95%)

Total5732 (56.14%)10 (17.54%)8 (14.04%)7 (12.28%)

0: <10%; 1: 10–25%; 2: 25–50%; 3: >50%.